Study: J&J ($JNJ) heart drug is safe but ineffective

Talk about a backhanded compliment for Johnson & Johnson ($JNJ). A big new trial of its congestive heart failure treatment Natrecor trumped worries that the drug might be linked to kidney failure and death. That's the good part; the trial also showed, however, that Natrecor is a mediocre performer at best.

According to data presented at the American Heart Association meeting, 15 percent of patients treated with Natrecor (nesiritide) for shortness of breath got significant relief after six hours, compared with 13.4 percent of patients treated with placebo. At the end of 24 hours, 30.4 percent of Natrecor patients were better, compared with 27.5 percent of placebo. And at the end of 30 days, 3.6 percent of Natrecor patients died compared with 4 percent of placebo patients.

"There is no evidence that [Natrecor] is associated with an increased risk of mortality," Harvard cardiologist Eugene Braunwald said at a news conference (as quoted by the Los Angeles Times). "The less good news is that the trial provides very little evidence that a physician would improve the outcome of a patient who is receiving good standard care [by using it]."

Meanwhile, a different trial found that off-label use of Natrecor for mild heart failure wasn't effective, either. Already, Natrecor sales have dropped to about $100 million annually from a high of $230 million on those safety concerns. Will the drug suffer even more on this new data? Some doctors told the Wall Street Journal that Natrecor will still be useful for some patients, depending upon individual breathing symptoms, and now they don't have to worry about safety. So only time will tell.

- read the LATimes story
- get more from the Wall Street Journal
- see the Forbes coverage

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…